血清最低度值和危急病患者中塞福拉诱导的凝血病的危险因素:一个回顾性病例对照研究
Qian Wang1,2, Pei Liang3, Ying Xu4
1Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
European journal of clinical pharmacology
|February 14, 2024
概括
在重症患者中,塞福拉佐诱导的凝血病常常发生在第6天左右. 高APACHE II分数,肝脏问题和血清度超过87.765毫克/升增加风险,而维生素K1具有保护作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
- 临床化学 临床化学
背景情况:
- 塞福拉是一种在重症监护机构使用的抗生素.
- 凝血病是某些抗生素的潜在不良影响,包括塞福拉.
- 鉴定佩拉诱导的凝血病的风险因素和值对于患者的安全至关重要.
研究的目的:
- 在重症患者中识别 cefoperazone 诱导的凝血病的危险因素.
- 为了确定与这种不良事件相关的血清最低度值.
- 为了评估维生素K1的疗效,进行了预防.
主要方法:
- 一个回顾性病例控制研究,涉及113名重症监护病房患者,接受了塞福拉治疗.
- 患者被分为正常和凝血病组,基于前列血时间.
- 使用单变量分析,ROC曲线分析和多变量逻辑回归来分析数据.
主要成果:
- 塞福拉诱导的凝血病发病率为34.5% (39/113名患者),中位数发病于6日左右.
- 凝血病的血清最低度值为87.765毫克/升.
- 风险因素包括较高的APACHE II分数,肝功能障碍和血清度≥87.765 mg/L;预防性维生素K1具有保护作用.
结论:
- 塞福拉诱导的凝血病通常在重症患者的第6天左右表现出来.
- 患有APACHE II评分>25的患者,肝功能障碍,以及塞福拉的最低度≥87.765毫克/升的患者有增加的风险.
- 预防性给予维生素K1有效防止这种不良反应.
相关概念视频
Drug Concentration Versus Time Correlation
768
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
768
Therapeutic Index
4.3K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.3K
Renal Failure: Dose Adjustments
89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89
Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Factors Affecting Protein-Drug Binding: Patient-Related Factors
59
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
59
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K


